# Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

> **NCT01509053** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole (Abilify®) IM Depot Injection
- **DRUG:** Oral aripiprazole

## Key facts

- **NCT ID:** NCT01509053
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509053, "Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01509053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*